pocketful logo
Ind-Swift Laboratories Ltd logo

Ind-Swift Laboratories Ltd

NSE: INDSWFTLAB BSE: 532305

₹141.51

(-0.41%)

Sat, 21 Mar 2026, 09:11 pm

mtf coin illustrationMTF 5x

Company History

2000

  • The Company developed a new drug ASTROVASTATIN.
  • The Company allotted 7,43,300 non-cumulative, redeemable preference shares to promoters and associates.
  • The Unit Trust of India picked up 5,00,000 equity shares of the company.
  • The Company entered into exclusive marketing agreements with major international pharma companies.
  • Ind-Swift Laboratories agreed to source requirements for Clarithromycin, Fexofenadine, Roxithromycin, and Candesartan from international pharmaceutical companies.

2002

  • The Board forfeited 1,75,900 equity shares on which allotment money was due since 19th July, 1997.

2003

  • The board approved the issue of 2322750 equity shares upon conversion of preference shares into equity shares.
  • Ind-Swift Ltd., the promoter company, disinvested 386930 equity shares of the company.

2004

  • The Company set up a subsidiary in the US.
  • Ind-Swift Laboratories shifted its corporate and head office to SCO 850, Shivalik Enclave, NAC, Manimajra, Chandigarh - 160101.
  • The Company received the achievement award for the Best Performing Company in Category E by the Express Pharma Pulse.
  • Ind Swift Laboratories entered into long-term agreements for the supply of APIs.
  • The Company won the Deloitte Fast 500 Award 2004 in Hong Kong.

2005

  • Ind Swift Laboratories put three new units into operation.
  • The Company recommended a dividend of 15%.

2006

  • Ind Swift Laboratories inaugurated its state of art R&D centre.
  • Ind-Swift Labs opened an R&D centre in Mohali.
  • The Company recommended a dividend of 15% on the equity shares and Re 1/- per share on the preference shares.
  • The Company received the Bhartiya Udyog Rattan Award for its contribution to society and national development.

2007

  • The Company successfully completed USFDA inspection for Clarithromycin API manufacturing facility.
  • The Company recommended a dividend of 10% on the Equity Shares of the Company.

2008

  • The Board recommended a dividend of 10% on the Equity Shares of the Company.
  • Sh. S.R. Mehta was nominated as the Chairman of the Company.
  • Sh. N.R. Munjal was nominated as the Vice-Chairman of the Company.
  • Sh. V.K. Mehta was nominated as the Managing Director of the Company.
  • The Registered Office of the Company was shifted to SCO 850, Shivalik Enclave, NAC, Manimajra, Chandigarh - 160101.

2009

  • The Board recommended a dividend of 10% on the Equity Shares of the Company.
  • The Company appointed Mr. H P S Chawla, Mr. N D Aggarwal, and Mrs. Nirmal Aggarwal as Independent Directors.

2010

  • The Board recommended a dividend of Rs. 1/ per share of Rs. 10/- each.
  • Dr. N. P. Singh was appointed as an Independent Director.

2011

  • Ind-Swift Laboratories received TGA approval from Australia for its seven APIs.
  • Ind-Swift Labs filed two more DMFS with USFDA.
  • The Board recommended a dividend of Rs 1/- per share on Equity Shares of Rs.10/- each.
  • Ind-Swift Laboratories received PMDA approval for Pioglitazone and Risedronate Sodium from the Government of Japan.

2012

  • Ind-Swift Laboratories launched generic formulations of the drug Atorvastatin in the UK in collaboration with Wockhardt UK Ltd.
  • Ind-Swift Labs received USFDA approval for 5 APIs for its Derabassi facility.
  • Ind-Swift Labs got its first order for contract research.
  • Ind-Swift Labs received PMDA approval for Pioglitazone and Risedronate Sodium from the Government of Japan.

2013

  • R K Ummat was appointed as an Independent Director on the Board of the Company.

2014

  • Dr. Vinay Kumar Arora was appointed as an Independent Director.

2018

  • The company acquired KEC Bikaner Sikar Transmission Private Limited.

2020

  • Ind-Swift Labs tied up with a reputed generic player in the USA to launch generic Fexofenadine.

2021

  • Ind-Swift Laboratories Limited received the North India Best Employer Award.

Open Your Free Demat Account Now!

Step into a world of zero fees and limitless opportunities!

pocketful logo

2022-25 Pocketful. All rights reserved, Built with in India

Version -5.76

app image 1app image 2

Stocks:

AllABCDEFGHIJKLMNOPQRSTUVWXYZ

Explore

Calculatorsfooter arrow down icon
Popular Calculatorsfooter arrow down icon
Group Stocksfooter arrow down icon

Others:

NSEBSECDSLNSDLSEBIMCXMSEINCDEXNSE IFSCINDIA INXAccount Closure FormDP Investor CharterBroker Investor Charter

Pocketful Fintech Capital Private Limited (CIN U65999DL2021PTC390548) | The SEBI Registration No. allotted to us is INZ000313732. NSE Member Code: 90326 | BSE Member Code: 6808 | MCX Member Code: 57120 DP | CDSL: 12099800